Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial

被引：42

作者：

Schneider, LS ^{[1
]}

Ismail, MS ^{[1
]}

Dagerman, K ^{[1
]}

Davis, S ^{[1
]}

Olin, J ^{[1
]}

McManus, D ^{[1
]}

Pfeiffer, E ^{[1
]}

Ryan, JM ^{[1
]}

Sultzer, DL ^{[1
]}

Tariot, PN ^{[1
]}

机构：

[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA

来源：

SCHIZOPHRENIA BULLETIN | 2003年 / 29卷 / 01期

关键词：

Alzheimer's disease; atypical antipsychotic; psychosis; dementia; effectiveness;

D O I：

10.1093/oxfordjournals.schbul.a006991

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

This article describes the development of the protocol for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer's disease trial, which was developed in collaboration with the National Institute of Mental Health to assess the effectiveness of atypical antipsychotics for psychosis and/or agitation occurring in outpatients with Alzheimer's disease. The article provides a detailed description of the methodology used in the trial as well as the clinical outcomes and effectiveness measures incorporated into it, discussing the most salient issues encountered in developing the design of the trial, as well as the unique features of the trial.

引用

页码：57 / 72

页数：16

共 50 条

[31] The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer's Disease
Calsolaro, Valeria
Antognoli, Rachele
Okoye, Chukwuma
Monzani, Fabio
FRONTIERS IN PHARMACOLOGY, 2019, 10
[32] Alzheimer's disease multiple intervention trial (ADMIT): study protocol for a randomized controlled clinical trial
Callahan, Christopher M.
Boustani, Malaz A.
Schmid, Arlene A.
Austrom, Mary G.
Miller, Douglas K.
Gao, Sujuan
Morris, Carrie S.
Vogel, Mickey
Hendrie, Hugh C.
TRIALS, 2012, 13
[33] Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials
Tam, A.
Laurent, C.
Gauthier, S.
Dansereau, C.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2022, 9 (03): : 400 - 409
[34] Socioeconomic disparities in clinical trials on Alzheimer's disease: a systematic review
Canevelli, M.
Bruno, G.
Vico, C.
Zaccaria, V.
Lacorte, E.
Iavicoli, I.
Vanacore, N.
Cesari, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (04) : 626 - +
[35] Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease
Seo, Younghoon
Jang, Hyemin
Lee, Hyejoo
LIFE-BASEL, 2022, 12 (02):
[36] Informed consent, therapeutic misconception, and clinical trials for Alzheimer's disease
Wilkins, James M.
Forester, Brent P.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2020, 35 (05) : 430 - 435
[37] Attitudes toward clinical trials across the Alzheimer's disease spectrum
Nuno, Michelle M.
Gillen, Daniel L.
Dosanjh, Kulwant K.
Brook, Jenny
Elashoff, David
Ringman, John M.
Grill, Joshua D.
ALZHEIMERS RESEARCH & THERAPY, 2017, 9
[38] Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials
Rollin-Sillaire, Adeline
Breuilh, Laetitia
Salleron, Julia
Bombois, Stephanie
Cassagnaud, Pascaline
Deramecourt, Vincent
Mackowiak, Marie-Anne
Pasquier, Florence
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (04) : 1089 - 1097
[39] Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, Michael W.
Kanoria, Shaveta
Miller, Melanie J.
Aisen, Paul S.
Beckett, Laurel A.
Conti, Catherine
Diaz, Adam
Flenniken, Derek
Green, Robert C.
Harvey, Danielle J.
Jack Jr, Clifford R.
Jagust, William
Lee, Edward B.
Morris, John C.
Nho, Kwangsik
Nosheny, Rachel
Okonkwo, Ozioma C.
Perrin, Richard J.
Petersen, Ronald C.
Rivera-Mindt, Monica
Saykin, Andrew J.
Shaw, Leslie M.
Toga, Arthur W.
Tosun, Duygu
Veitch, Dallas P.
Alzheimers Disease Neuroimaging Initiative
ALZHEIMERS & DEMENTIA, 2025, 21 (01)
[40] Alzheimer’s disease multiple intervention trial (ADMIT): study protocol for a randomized controlled clinical trial
Christopher M Callahan
Malaz A Boustani
Arlene A Schmid
Mary G Austrom
Douglas K Miller
Sujuan Gao
Carrie S Morris
Mickey Vogel
Hugh C Hendrie
Trials, 13

← 1 2 3 4 5 →